Completion lymphadenectomy in melanoma
CLND; immediate completion node dissection; therapeutic lymphadenectomy (for clinically involved nodes)
Completion lymphadenectomy is the surgical clearance of a regional nodal basin after a positive sentinel node. For decades it was the routine response to a positive SLN, on the assumption that further occult disease was likely in the basin. Two landmark randomised trials — MSLT-II (Faries 2017) and DeCOG-SLT (Leiter 2016) — demonstrated no melanoma-specific survival benefit from immediate CLND compared to nodal-basin ultrasound observation, while CLND substantially increased lymphoedema. UK practice has therefore changed: most SLN-positive patients are now offered ultrasound surveillance of the nodal basin (and adjuvant systemic therapy) rather than CLND. Therapeutic lymphadenectomy for clinically or radiologically detected nodal disease remains an important operation.
Historical context — pre-MSLT-II
- Before 2017, completion lymph node dissection was offered routinely to all SLN-positive patients on the assumption of nodal control benefit.
- Approximately 70–80% of SLN-positive patients had no further nodal disease at CLND, but suffered the morbidity of basin clearance.
- Adjuvant interferon was the only systemic option until anti-CTLA-4 (ipilimumab, 2015) and anti-PD-1 / BRAF-targeted therapy (2018+) — modern adjuvants have changed the calculus.
MSLT-II and DeCOG-SLT evidence
- MSLT-II (Faries, NEJM 2017) — randomised 1934 SLN-positive patients to immediate CLND vs nodal-basin ultrasound surveillance. 3-year melanoma-specific survival 86% in both arms; CLND associated with 24% lymphoedema vs 6% surveillance. Greater number of node-positive patients identified in CLND arm did not translate to survival.
- DeCOG-SLT (Leiter, Lancet Oncol 2016) — 483 SLN-positive patients with pT1–pT3 melanoma. No DFS or MSS benefit from immediate CLND.
- Combined evidence: routine immediate CLND no longer recommended.
Current UK practice (NICE NG14)
- Nodal observation with ultrasound is the default for most SLN-positive patients.
- NICE NG14: for stage IIIA–IIIC patients not currently having adjuvant therapy, offer the stage III clinic / CE-CT schedule; if the sentinel node was positive, consider 2 nodal-basin ultrasound scans per year in years 1–3. During adjuvant therapy, base follow-up on therapeutic requirements.
- Immediate CLND may still be considered at MDT discretion in selected high-risk subgroups:
- Multiple positive sentinel nodes.
- Large tumour burden (> 1 mm deposit) with extranodal extension.
- Patient unable to attend US surveillance.
- Anticipated difficulty of later salvage (anatomical considerations).
- Therapeutic lymphadenectomy for clinically or radiologically detected nodal disease (palpable node, US-suspicious node with FNA positive) remains standard care.
Technique
- Axillary clearance — levels I–III; preserve long thoracic and thoracodorsal nerves; protect axillary vein.
- Inguinal clearance — superficial groin nodes; pelvic (deep) dissection considered when Cloquet node is involved or imaging/biopsy shows deep disease.
- Neck dissection — modified radical or selective depending on the primary site and basin.
- Closed-suction drainage; lymphoedema prevention measures from the immediate post-op period.
Adverse effects
- Lymphoedema — 20–30% after axillary, 30–50% after inguinofemoral, 5–10% after neck dissection.
- Seroma, wound infection, haematoma, dehiscence — basin-specific.
- Nerve injury — intercostobrachial (axilla), femoral cutaneous (groin), spinal accessory (neck).
- Functional impairment of shoulder, hip or neck range of movement.
References
- Faries MB et al. Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II). N Engl J Med; 2017;376:2211–22.
- Leiter U et al. Complete lymph node dissection vs no dissection in melanoma (DeCOG-SLT). Lancet Oncol; 2016;17:757–67.
- NICE NG14. Melanoma: assessment and management. London: NICE; 2015 (last updated 27 July 2022).
Spot a correction?
If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.